mrg004a
mAbexperimentalADC
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jul 26, 2021 (NCT04843709)
Timeline
Indications
Mechanism of action
- Coagulation factor IIIBINDING AGENT
F3 binding agent
Chemistry & pharmacology
- Payload
- Unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07138846 | Phase 3 | Jan 31, 2026 | Fudan University, Shanghai Miracogen Inc. |
| NCT04843709 | Phase 1/Phase 2 (Phase 2) | Jul 26, 2021 | Gabrail Cancer Center, Shanghai Miracogen Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Miracogen Inc. | For profit | 2 | 2 | 2 | 2021 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2026 |
| Gabrail Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1